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34039
Maintenance of skin clearance in a long-term open-label study of
fixed-combination halobetasol propionate and tazarotene lotion
for psoriasis in participants with prior use of topical treatments
Linda Stein Gold, MD, Henry Ford Hospital; Javier Alonso-Llamazares,
MD, Driven Research; Joshua Zeichner, MD, Mount Sinai Hospital
Background: Most patients with psoriasis are dissatisfied with their current
treatment, primarily because of limited effectiveness. This post hoc subgroup
analysis evaluated long-term efficacy and safety of fixed-combination halobetasol
propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) in participants with
use of topical corticosteroid (TCS; 137/550 [24.9%]) or other antipsoriatic topical
medications (51/550 [9.3%]) before entry in an open-label study of HP/TAZ
(NCT02462083).
Methods: Participants in the open-label study received HP/TAZ once daily. At week
8, participants who achieved treatment success (investigator’s global assessment
[IGA] score of 0 or 1) stopped treatment and were reevaluated monthly through 52
weeks; those who did not achieve treatment success continued HP/TAZ. Twentyfour continuous weeks of treatment were allowed if participants achieved $1-grade
improvement in IGA from baseline at week 12, with monthly reevaluation. If at any
point the condition intensified to IGA $2, HP/TAZ was resumed, otherwise, HP/TAZ
was discontinued.
Results: From weeks 8 to 52, similar treatment success rates were achieved by
participants with prior use of TCS (range, 20.0%-40.0%) or other topicals (range,
21.1%-53.8%). Mean affected body surface area at baseline was 5.7% and 5.5%,
respectively, and decreased to 3.8% and 2.4%, respectively, at week 52. Percentage of
participants who maintained disease control for 29 to 85 days after HP/TAZ
cessation was comparable. Rates of adverse events were similar between groups.
Conclusions: Regardless of the type of previous topical therapy, participants with
prior use of topical medications maintained skin clearance with HP/TAZ over 52
weeks.
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Malignancy risk among children and adults with atopic dermatitis in a population-based cohort
Joy Wan, MD, MSCE, Department of Dermatology, University of
Pennsylvania Perelman School of Medicine; Daniel B. Shin, PhD,
Department of Dermatology, University of Pennsylvania Perelman School of
Medicine; Maha N. Syed, MBBS, Department of Dermatology, University of
Pennsylvania Perelman School of Medicine
Atopic dermatitis (AD) is linked to immunologic dysfunction which may influence
cancer risk. Few epidemiologic investigations of AD and cancer have included
pediatric populations or accounted for AD severity. We conducted a populationbased cohort study using a U.K.-based medical records database to examine the risk
of malignancy among children and adults with AD. 409,431 children and 625,083
adults with AD were matched on age, practice, and index date to 1,809,029 children
and 2,678,888 adults without AD, respectively. AD severity was estimated as mild,
moderate, or severe using treatments as a proxy. Among children, the risk of any
incident malignancy did not differ by AD status (HR 1.02 [95% CI 0.92-1.12]).
However, children with moderate or severe AD had a significantly greater risk of
lymphoma compared with children without AD (HRs 1.71 [1.01-2.90] and 3.13
[1.39-7.06], respectively). Among adults, overall malignancy risk did not differ by AD
status (HR 1.00 [0.99-1.02]) but severe AD was associated with a 15% greater risk of
cancer relative to no AD (1.15 [1.10-1.20]). Adults with moderate or severe AD had
significantly greater risk of lymphoma (HRs 1.19 [1.10-1.30] and 2.28 [1.92-2.71],
respectively). Adults with moderate AD had lower risk of solid organ malignancy
(HR 0.93 [0.92-0.95]), including bladder, breast, colon, lung, and prostate cancer. In
summary, AD is associated with increased risk of select cancers, particularly
lymphoma, and potentially lower risk of some solid malignancies, suggesting a
heterogeneous relationship between AD and cancer that requires deeper investigation as immunomodulatory therapies continue to emerge for AD.
Commercial Disclosure: The study was supported by a grant from Pfizer paid to
the Trustees of the University of Pennsylvania.

Commercial Disclosure: This study was sponsored by Ortho Dermatologics.
Medical writing support was provided by MedThink SciCom and funded by
Ortho Dermatologics. Ortho Dermatologics is a division of Bausch Health US,
LLC.

31256
Malignancy rates through 5 years of follow-up in guselkumabtreated patients with moderate to severe psoriasis: Results from
the VOYAGE 1 and 2 trials and comparisons to general
populations
Andrew Blauvelt, Oregon Medical Research Center, Portland, OR; Richard G.
Langley, Dalhousie University, Halifax, Nova Scotia, Canada; Vincent Ho,
Department of Dermatology and Skin Science, University of British Columbia,
Vancouver, BC, Canada
Introduction: Surveillance of malignancy risk among patients receiving long-term
immunomodulatory treatment remains an important safety objective. Here we
report malignancy rates in patients with moderate-to-severe psoriasis treated with
guselkumab for up to 5 years versus a representative psoriasis registry population
and the general US population.
Methods: Cumulative rates of malignancies/100 patient-years (PY) were evaluated in
1721 guselkumab-treated patients from VOYAGE-1&2. Overall rates of malignancies
excluding NMSC were compared with rates among patients eligible for systemic
therapy from the Psoriasis Longitudinal Assessment and Registry (PSOLAR; 20072014; N ¼ 12,093; [40,000 PY). Standardized incidence ratios (SIRs; 95%CI)
comparing rates of malignancies excluding NMSC and cervical cancer in situ
between guselkumab-treated psoriasis patients and the general US population using
Surveillance, Epidemiology, and End Results data (2000-2017) were calculated,
adjusting for age, sex, and race.
Results: Of 1721 guselkumab-treated patients included in VOYAGE-1&2 (7166PY of
follow-up), 24 had NMSC (0.34/100PY) and 32 had malignancies excluding NMSC
(0.45/100PY). For comparison, the rate of malignancies excluding NMSC was
0.68/100PY in PSOLAR. The rate of malignancies (excluding NMSC/cervical cancer
in situ) in guselkumab-treated patients was generally consistent with that expected
in the general US population [SIR (95% CI) ¼ 0.93 (0.64-1.31)]; the most commonly
reported malignancies in guselkumab-treated patients were breast [n ¼ 6; SIR ¼ 1.47
(0.54-3.20)], colorectal [n ¼ 5; SIR ¼ 1.54 (0.50-3.59)], melanoma [n ¼ 4; SIR ¼ 1.32
(0.36-3.39)], and prostate [n ¼ 4; SIR ¼ 0.59 (0.16-1.50)].
Conclusions: Through 5 years of treatment of psoriasis patients with guselkumab in
VOYAGE-1&2, NMSC and other malignancy rates were low. Malignancy rates
(excluding NMSC) were generally consistent with rates expected in the general
US population and observed in the PSOLAR registry.
Commercial Disclosure: 100% sponsored by Janssen Research & Development,
LLC.
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Management of common scabies and post-scabetic itch in adults:
Lessons learned from a single-center retrospective cohort study
Le Wen Chiu, BS, University of California San Francisco, School of
Medicine; Tim G. Berger, MD, University of California San Francisco,
Department of Dermatology; Aileen Y. Chang, MD, University of California San
Francisco, Department of Dermatology
Background: Limited data exist on clinical characteristics and treatment outcomes of
patients with common scabies who are treated with combined topical permethrin
plus oral ivermectin. Post-scabetic itch is common, but there is scant data describing
its prognosis and management.
Methods: We conducted a single-center retrospective cohort study of adult
participants with common scabies treated with combined topical permethrin plus
oral ivermectin therapy compared with topical permethrin only. Participants
previously treated with permethrin and/or ivermectin were excluded. The primary
outcome was clinical outcome at follow-up, categorized as cure, worsening, or no
change. Secondary outcomes included time from treatment initiation to cure,
duration of follow-up after cure, recurrence rate, frequency of post-scabetic itch,
and duration of post-scabetic itch.
Results: Of 55 participants treated with combined topical permethrin plus oral
ivermectin, 49 (89%) achieved cure, 5 (9%) had no change, and 1 (2%) had
worsening disease. Of 48 treated with topical permethrin only, 46 (96%) achieved
cure, 2 (4%) had no change, and 0 (0%) had worsening disease. Thirty-five (34%)
experienced post-scabetic itch for 52.5 days (interquartile range, 28-135). More
participants in the older (mean [standard deviation {SD}] ¼ 55 [21] years, P ¼.002)
combined treatment group experienced post-scabetic itch than in the younger
(mean [SD] ¼ 42 [19] years) permethrin only treatment group (42% vs 25%, P ¼
.072).
Conclusions: These findings support use of combined topical permethrin plus oral
ivermectin therapy in treating common scabies, suggest post-scabetic itch can
persist for longer than previously reported, and reveal a potential relationship
between older age and post-scabetic itch.
Commercial Disclosure: None identified.
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